Treatment paradigms for patients with metastatic non small cell lung cancer (NSCLC), squamous lung cancer: first, second and third-line
Historically, the treatment algorithm applied to non small cell lung cancer (NSCLC) was the same for all histologic subtypes. However, recent advances in our understanding of the molecular profiles of squamous and non-squamous NSCLC have changed this perspective. Histologic subtype and the presence...
Main Authors: | Abdulaziz eAl Farsi, Peter Michael Ellis |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00157/full |
Similar Items
-
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies
by: Sarah L Scarpace
Published: (2015-10-01) -
An exceptional response to immunotherapy with chemotherapy in metastatic lung cancer
by: Xenia Elena BACINSCHI, et al.
Published: (2020-06-01) -
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
by: Ying Cheng, MD, et al.
Published: (2021-10-01) -
PROMISING TARGETS AND CURRENT CLINICAL TRIALS IN METASTATIC SQUAMOUS CELL LUNG CANCER
by: Mark eVincent
Published: (2014-12-01) -
Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
by: Rachel Ryu, et al.
Published: (2018-07-01)